A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Muhtasari wa habari
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Fuatilia habari za hivi karibuni kutoka kwa wachapishaji wanaoaminika pamoja na muhtasari mfupi. Fungua chanzo asili kwa maelezo.